Needham’s healthcare analyst Alan Carr weighed in this morning with a few insights on Gilead Sciences (NASDAQ:GILD), as the company is scheduled to report its …
In a research report released today, analyst Rajvindra Gill of Needham reiterated a Buy rating on Micron Technology (NASDAQ:MU) with a $60 price target, as …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Hold rating on KaloBios Pharmaceuticals (NASDAQ:KBIO), as the company yesterday …
Needham analyst Alan Carr weighed in today on shares of Cempra (NASDAQ:CEMP) maintaining a Buy rating and raising the price target to $42 (from $28), as the company announced positive …
In a research report released Monday, Needham analyst Rajvindra Gill reiterated a Buy rating on Nvidia Corporation (NASDAQ:NVDA) with a $25 price target, as this …
In a research report issued today, Needham analyst Alan Carr maintained a Hold rating on Cubist Pharmaceuticals (NASDAQ:CBST), following last Friday’s news that the …
In a research report sent to investors today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) and raised his price target …
In a research report published this morning, Needham analyst Alan Carr maintained a Buy rating on Acadia (NASDAQ:ACAD) and raised his price target …
In a research report released today, Needham analyst Alan Carr reiterated a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a price target of …
